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Abstract
Skeletal muscle is essential for normal bodily function and the loss of skeletal muscle (i.e. muscle atrophy/
wasting) can have a major impact on mobility, whole-body metabolism, disease resistance, and quality of
life. Thus, there is a clear need for the development of therapies that can prevent the loss, or increase, of
skeletal muscle mass. However, in order to develop such therapies, we will first have to develop a
thorough understanding of the molecular mechanisms that regulate muscle mass. Fortunately, our
knowledge is rapidly advancing, and in this review, we will summarize recent studies that have expanded
our understanding of the roles that Smad signaling and the synthesis of phosphatidic acid play in the
regulation of skeletal muscle mass.
The importance of skeletal muscle
Skeletal muscle plays essential roles in the human body,
including the generation of limb, trunk, and eye move-
ments and the control of breathing. Furthermore,
because skeletal muscle makes up such a large, metabo-
lically active proportion of the body (~45%), it also
plays an important role in the regulation of whole-body
metabolism (e.g. systemic glucose control) [1,2]. As such,
the loss of skeletal muscle mass (i.e. muscle atrophy) can
have a major impact on mobility, whole-body metabo-
lism, disease resistance, and quality of life [3-5]. Muscle
atrophy occurs in many commonly occurring conditions
(e.g. injury-induced immobilization, severe burns, cancer
cachexia, aging, heart failure, obesity, diabetes, chronic
obstructive pulmonary disease, renal disease, and HIV) and
can be induced by changes in a variety of factors, including
nutrients, neural activity, cytokines, growth factors, hor-
mones, and mechanical loading [4-9]. Thus, there is clearly
a need for therapies that can prevent the loss, or increase,
of skeletal muscle mass. However, in order to develop
such therapies, we will first have to develop a thorough
understanding of the molecular mechanisms that regulate
muscle mass.
In recent years, significant progress has been made in
identifying potential molecular signaling mechanisms
that regulate skeletal muscle mass under a range of
different conditions (for recent reviews, see [10-22]). In
this review, we will summarize the major advancements
that have beenmade in our understanding of the roles that
Smad signaling and the synthesis of phosphatidic acid
(PA) play in the regulation of muscle mass (Figure 1).
For further background information on these two areas
of investigation, the reader is referred to the following
reviews: [23-27].
The role of Smad signaling in the regulation of
skeletal muscle mass: recent advances
Myostatin-induced Smad2/3 signaling and the regulation
of skeletal muscle mass
Canonical Smad signaling is regulated by members of the
transforming growth factor-beta (TGF-b) superfamily of
receptor ligand proteins. For example, Smad2/3 signaling
is activated by members of the TGF-b and activin sub-
families and by some members of the growth differentia-
tion factor (GDF) subfamily, whereas Smads 1/5/8 are
activated by members of the bone morphogenic protein
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Figure 1. A general overview of recent findings related to Smad signaling and the synthesis of phosphatidic acid in the regulation of
skeletal muscle mass
Increases in transforming growth factor-beta (TGFb), activins, and some growth and differentiation factors (GDFs), such as myostatin, lead to receptor-
mediated phosphorylation of Smads 2 and 3, whereas increases in bone morphogenic proteins (BMPs) and other GDFs result in increased Smad 1, 5, and 8
phosphorylation. Phosphorylated Smads 2/3 compete with phosphorylated Smads 1/5/8 for binding to Smad4 before entering the nucleus to regulate gene
transcription. Increased Smad2/3/4 signaling inhibits Akt/mTORC1 signaling and activates the expression of ubiquitin proteasome E3 ligases, atrogin-1 and
muscle RING-finger protein-1 (MuRF1), ultimately leading to a decrease in protein synthesis and increased protein degradation. Increased Smad1/5/8/4
signaling activates Akt/mechanistic target of rapamycin complex 1 (mTORC1) signaling and represses the histone deacetylase 4 (HDAC4)/myogenin-mediated
activation of E3 ligases (including MUSA1) under atrophic conditions, such as denervation. The net balance between Smad2/3/4 and Smad1/5/8/4 signaling
appears to play a major role in determining skeletal muscle mass. The enzyme phospholipase D1 (PLD1) synthesizes PA, and PLD1 overexpression activates
mTORC1 signaling and represses the expression of the E3 ligases, atrogin-1 and MuRF1. The zeta isoform of diacylglycerol kinase (DGKz) also synthesizes
PA and is required for a mechanically induced increase in PA and the subsequent activation of mTORC1. See text (“Bone morphogenic protein-induced
Smad1/5/8 signaling and the regulation of skeletal muscle mass” section) for a more detailed explanation of these molecular signaling mechanisms.
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(BMP) and GDF subfamilies [28,29] (Figure 1). Initial
interest in the role of Smad signaling in the regulation of
skeletal muscle mass largely stemmed from the discovery
that the disruption of the GDF-8 (also known as the
myostatin) gene, and the inhibition of myostatin receptor
binding, produced marked skeletal muscle hypertrophy
[30,31]. Furthermore, it has since been shown that an
increase in myostatin is often associated with skeletal
muscle atrophy [32,33] and an increase in Smad3
phosphorylation [34]. Combined, these studies suggested
that myostatin is a negative regulator of skeletal muscle
mass and that Smad signaling may, in part, mediate this
effect.
Myostatin-mediated Smad signaling is activated by
the binding of the mature myostatin peptide to plasma
membrane-associated activin type IIB and, to a lesser
extent, type IIA receptors (ActRIIB/IIA) (Figure 1) [35].
The activation of ActRIIB/IIA receptors leads to the recruit-
ment and activation of serine/threonine type 1 receptor
kinases called activin receptor-like kinase-4 and -5 (ALK4
and ALK5), which phosphorylate the transcription factors
Smad2 and 3 [35]. Phosphorylated Smad2 or 3 can then
form a heterotrimeric complex with another Smad2 or 3,
and a Smad4, and the resulting complex translocates to the
nucleus to regulate gene transcription by associating with
various transcription factors, co-activators, or co-repressors
[36] (Figure 1). Smad2 and 3 are also phosphorylated in
response to TGF-b and activin binding to TGF-b type II
receptors (TGF-bRII) and ActRIIA/IIB receptors which,
in turn, leads to the activation of ALK5 and ALK4/7,
respectively [37,38] (Figure 1).
The necessity for Smad signaling in myostatin/activin/
TGF-b-induced muscle atrophy in vivo was first demon-
strated by Sartori et al. (2009), who showed that the
overexpression of a constitutively active mutant of ALK5
(caALK5) increased the promoter activity of the muscle-
specific ubiquitin proteasome E3 ligase atrogin-1 gene
and inducedmuscle fiber atrophy via a Smad3-dependent
mechanism [39]. Furthermore, Smad3 has been found to
be necessary for myostatin-induced increases in atrogin-1
expression and atrophy of cultured myotubes [40,41].
Other studies have also shown that increased myostatin
is sufficient to induce a decrease in protein synthesis,
possibly by promoting the atrogin-1-mediated degradation
of ribosomal proteins and translation initiation factors or
via the inhibition of signaling through the protein kinase
B (Akt) and mechanistic target of rapamycin complex 1
(mTORC1) pathway [40-49] or both. Importantly, it has
been demonstrated that Smad3 signaling is necessary for
the myostatin-induced inhibition of the Akt/mTORC1
pathway [40,50]. Combined, these data suggest that
myostatin-induced muscle atrophy may be due, in part,
to a combinationof Smad3-mediated increases in atrogin-1
expression and the inhibition of Akt/mTORC1 signaling
[41,51,52] (Figure 1). However, while Smad3 was shown
to be necessary for these events, it remained to be deter-
mined whether Smad3 is sufficient to induce these events
in vivo or whether Smad3 merely plays a permissive role.
To address the issue of whether Smad3 is sufficient to
inducemany of the reported effects of increasedmyostatin
signaling, we overexpressed Smad3 in vivo and demon-
strated that this was sufficient to activate the atrogin-1
promoter, inhibit mTORC1 signaling and protein synth-
esis, and ultimately induce muscle fiber atrophy [53].
Furthermore, we and others have recently presented
evidence that the myostatin/Smad3-induced decrease in
Akt/mTORC1 signaling may be mediated by a decrease in
the expression of microRNAs (i.e. miR29 or miR486 or
both) that normally inhibit the translation of the Akt
signaling antagonist, phosphatase and tensin homologue
(PTEN) [53,54]. Thus, combined with previous studies,
these results demonstrated that Smad3 is both necessary
and sufficient to regulate many of the previously reported
myostatin-induced events. Furthermore, the results of this
study suggest that Smad3 signaling may be a viable target
for therapies aimed at ameliorating many of the detri-
mental effects of increased myostatin, activin, or TGF-b
expression (or a combination of these) on skeletal muscle.
Bone morphogenic protein-induced Smad1/5/8 signaling
and the regulation of skeletal muscle mass
While there has been a significant amount of research
aimed at identifying the factors that regulate themyostatin-
Smad3 signaling axis, there has been comparatively less
investigation into the potential role(s) of BMP signaling
in mature skeletal muscle. BMP signaling is initiated by
the binding of BMP ligands to heterodimeric membrane
receptor complexes, made up of specific combinations of
type II (e.g. BMP type II receptor [BMPRII], ActRIIA, and
ActRIIB) and type I receptors (e.g. BMPRIA [ALK3],
BMPRIB [ALK6], and ActRIa [ALK2]), which, in turn,
leads to the phosphorylation of Smads 1, 5, and 8 [55]
(Figure 1). As with Smads 2/3, phosphorylated Smads 1/5/
8 form heterotrimeric complexes with Smad4, which then
translocates to the nucleus to regulate gene transcription.
Importantly, two recent studies have provided compelling
evidence that BMPs do indeed play a role inmature skeletal
muscle by regulating muscle mass through a Smad1/5/8-
dependent mechanism [56,57]. Specifically, it was shown
that the inhibition of BMP receptor signaling and the
knockdown of Smads 1 and 5 were sufficient to inhibit
Smad1/5/8 phosphorylation and induce muscle fiber
atrophy [56]. Furthermore, it was found that the over-
expression of BMP7 and caALK3 were sufficient to increase
Smad1/5/8 phosphorylation and induce substantial
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muscle fiber hypertrophy [56,57]. Importantly, these
hypertrophic responses were repressed by BMP receptor
inhibition and knockdown of Smad 1 and 5 [56,57].
Moreover, the overexpression of BMP7 and caALK3 was
sufficient to protect against denervation-induced muscle
atrophy [56,57]. Together, these data have provided strong
evidence that signaling by BMP can positively regulate
skeletal muscle mass.
The mechanisms responsible for the effects of BMP
signaling on muscle mass appear to be due, at least in
part, to increased activity of mTORC1 [57] (Figure 1).
Indeed, the overexpression of BMP7 and caALK3 was
associated with an increase in mTORC1 signaling (possi-
bly mediated by an increased insulin-like growth factor 1
[IGF-1]-induced Akt-phosphorylation), and BMP7-
induced muscle hypertrophy was completely prevented
by the mTORC1 inhibitor, rapamycin [57]. Although
these results underscore the central role of mTORC1 in
regulating skeletal muscle mass, further investigation is
required to firmly establish the link between increased
BMP signaling, IGF-1 expression, Akt phosphorylation,
and mTORC1 activation. Moreover, additional work is
needed to determine whether the hypertrophic effects of
BMP signaling are associated with an increase in protein
synthesis or a decrease in protein degradation or both.
Although these two studies provide clear evidence that the
overexpression of BMP and caALK3 is sufficient to regulate
muscle mass, they also present data showing that
endogenous BMP signaling plays a role in limiting the
extent of muscle loss that occurs during atrophic condi-
tions, such as denervation. Indeed, it was found that, in
denervated muscle, there was an increase in Smad1/5/8
phosphorylation and this was associated with an increase
in the expression of BMP13 (GDF6) and 14 (GDF5)
[56,57]. Furthermore, denervation-induced muscle fiber
atrophy was markedly exacerbated in BMP14 knockout
mice and in denervated wildtype mice in which BMP
signaling was inhibited with the BMP type I receptor
inhibitor, LDN-193189, or overexpression of inhibitory
Smad6 [56,57]. These data strongly suggest that endogen-
ous BMP signaling acts to protect skeletal muscle from
excessive atrophy. Interestingly, unlike the overexpression
of BMP7 and caAKL3, the mechanism behind the
endogenous BMP signaling-induced protection against
muscle atrophy does not seem to be related to an increase
in Akt/mTORC1 signaling [56,57]. Instead, this protective
effect appears to be due to the suppression of muscle-
specific ubiquitin proteasome E3 ligases, including the
recently identified MUSA1 (also known as Fbxo30)
[56,57]. For example, inhibition of BMP signaling via
overexpression of Smad6 or an extracellular BMP binding
protein called Noggin enhanced the increase in MUSA1
expression that occurs in response to denervation [56,57].
Furthermore, the knockdown of MUSA1 was sufficient to
protect against denervation-induced atrophy [56,57].
Mechanistically, BMP signaling may protect against the
induction of E3 ligases, such asMUSA1, by inhibiting hist-
one deacetylase 4 (HDAC4)-mediated myogenin expres-
sion [56,57], a signaling pathway that has also previously
been implicated in the expression of atrogin-1 andmuscle
RING-finger protein-1 (MuRF1) [58] (Figure 1). Com-
bined, the findings from these two recent studies [56,57]
highlight the potential for increasing BMP signaling as a
possible therapeutic approach for increasingmusclemass or
inhibiting muscle atrophy/wasting or both. One question
that remains to be answered is why Akt/mTORC1 signaling
was not enhanced by the increase in endogenous BMP
signaling found in denervated muscles but was enhanced
in innervated muscles subjected to the overexpression of
BMP7 and caALK3.
Finally, although these two recent BMP studies arrive at
different conclusions as to which Smad signaling branch
(i.e. myostatin/activin/TGF-b-Smad2/3 or BMP-Smad1/
5/8) is dominant under basal conditions (see [56,57] for
further details), a major conceptual contribution of these
studies is the hypothesis that the net balance between
these two pathways plays a major role in determining
skeletal musclemass. Furthermore, it appears that competi-
tion for Smad4 plays a central role in this balancing act [56]
(Figure 1). For example, under conditions of increased
myostatin, activin, or TGF-b signaling (or a combination of
these), an increase in phosphorylated Smads 2 or 3 or both
would effectively sequester a greater proportion of the
Smad4 pool and thus limit the ability of phosphorylated
Smads 1, 5, or 8 (or a combination of these) to form
Smad4-containing complexes, and vice versa. Therefore, an
increase in Smad2/3/4 complexes entering the nucleus,
combined with a decrease in nuclear Smad1/5/8/4 com-
plexes, would likely lead to an increase in the Smad2/3-
mediated transcriptional events that are reported to occur
under various atrophic conditions andadecrease inSmad1/
5/8-mediated anabolic events. As a result, the overall effect
would be a reduction in skeletal musclemass. Interestingly,
this hypothesis could also explain some of our recently
reported findings on the effect of Smad3 overexpression on
muscle fiber size (i.e. the overexpression of Smad3 may
have decreased BMP/Smad1/5/8 signaling) [53].
In summary, recent studies have significantly advanced
our understanding of the role that Smad signaling plays
in the regulation of skeletal muscle mass. In particular,
the discovery that BMP-Smad1/5/8 signaling plays a
significant role in the regulation of muscle mass, and the
finding that competition for Smad4may be fundamental
to the balance between catabolic myostatin/activin/TGF-
b-Smad2/3 and anabolic BMP-Smad1/5/8 signaling, will
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hopefully facilitate the development of pharmaceutical
or genetic therapies (or both) aimed at regulating Smad
signaling and preventing muscle wasting.
The role of phosphatidic acid in the regulation
of skeletal muscle mass: recent advances
PA is a glycerophospholipid second messenger that has a
diverse range of cellular functions, including the regulation
of cell growth (for review, see [59]). Indeed, in 2001, PA
was shown to activate mTORC1, a master regulator of
protein synthesis and cell growth [60,61]. Since then,
numerous studies have shown that the stimulation of cells
with exogenous PA, or the overexpression of PA-generating
enzymes, can activate mTORC1 signaling [62-66], whereas
blocking the generation of PA has been reported to inhibit
the activation of mTORC1 that occurs in response to
various types of stimuli [60,67-70]. Mechanistically, it has
been reported that PA can directly activatemTORC1 kinase
activity in vitro and this appears to be due to its ability to
bind to the FKBP12-rapamycin binding (FRB) domain of
mTOR [60,65,71,72].
PA can be synthesized by a number of different classes
of enzymes including the following: phospholipase D
(PLD), which synthesizes PA from phosphatidylcholine
(PC); lysophosphatidic acid acyltransferases (LPAAT),
which synthesize PA from lysophosphatidic acid (LPA);
and the diacylglycerol kinases (DAGKs), which synthe-
size PA from diacylglycerol (DAG) [59,66]. To date, the
number of studies that have examined the role of PA-
synthesizing enzymes in skeletal muscle is quite limited
(for reviews, see [25,26]); however, two recent studies
have significantly expanded our understanding of the
role of the PA-synthesizing enzymes, PLD1 and the zeta
isoform of DGK (DGKz), in the regulation of mTORC1
signaling and skeletal muscle mass [73,74] (Figure 1).
The synthesis of phosphatidic acid by phospholipase D1
as a regulator of skeletal muscle mass
In the first of these studies, the pharmacological
inhibition, and short interfering RNA (siRNA)-mediated
knockdown, of PLD1 was shown to induce atrophy in
cultured myotubes, suggesting that PA produced by
PLD1 is necessary for maintaining muscle mass [73].
Conversely, the overexpression of PLD1 was sufficient to
induce hypertrophy of myotubes and of muscle fibers in
vivo [73]. PLD1 overexpression was also able to inhibit
dexamethasone-induced myotube atrophy, whereas the
addition of exogenous PA inhibited myotube atrophy
induced by dexamethasone and tumor necrosis factor-
alpha (TNFa) [73]. Combined, these data provide strong
support for the hypotheses that PA derived from PLD1
contributes to the regulation of skeletal muscle mass and
that the activation of PLD1 has the potential to prevent
muscle atrophy. Mechanistically, it appears that PLD1
exerts effects on both protein synthesis and protein
degradation (Figure 1). For instance, the overexpression
of PLD1 was associated with an increase in mTORC1
signaling, whereas the siRNA-mediated knockdown of
PLD1 had the opposite effect [73]. As the activation of
mTORC1 signaling is known to be sufficient to increase
protein synthesis and induce muscle fiber hypertrophy
[75], these data suggest that PLD1-derived PA controls
skeletalmusclemass, in part, via the regulationofmTORC1
and protein synthesis. Interestingly, PLD1 overexpression
was also associated with a decrease in the expression of
FoxO3 and the E3 ligase genes, atrogin-1 and MuRF1 [73].
Moreover, the expression of these genes was increased
by pharmacological inhibition and knockdown of PLD1,
whereas the additionof exogenous PA attenuated the activa-
tion of these genes by dexamethasone [73]. The PLD1/PA-
induced inhibition of these atrophy genes appears to be due
to the activation of Akt, possibly via the activation of
the rapamycin-insensitive mTOR complex 2 (mTORC2)
[76-78]. For example, PLD1 overexpression was associated
with increased Akt phosphorylation, whereas the knock-
down of PLD1 had the opposite effect [73]. Combined,
these data suggest that PLD1-derived PA regulates skeletal
muscle mass via the activation of mTORC1 signaling
and protein synthesis and possibly by an mTORC2/Akt-
mediated inhibition of ubiquitin proteasome-mediated
protein degradation (Figure 1). Given that most of these
data were obtained from cultured myotubes, more research
is now required to confirm these findings in vivo. Never-
theless, the results of this study highlight that the activation
of PLD1/PA signaling may be a potential therapeutic
strategy for inducing muscle hypertrophy or preventing
muscle wasting or both.
The role of diacylglycerol kinase in the mechanical
activation of mechanistic target of rapamycin
complex 1 signaling
Not only is PLD/PA signaling implicated in the regula-
tion of basal skeletal muscle mass, but previous studies
have also suggested that this signaling pathway plays a
role in the activation of mTORC1 and protein synthesis
by mechanical stimuli [68,79]. For example, ex vivo
passive stretch, which activates mTORC1 signaling, has
been shown to increase PLD activity and the synthesis of
PA [68]. Furthermore, the stretch-induced increases in PA
and mTORC1 signaling were prevented when muscles
were incubated with the PLD inhibitor 1-butanol [68]. In
a separate study, in vivo eccentric contractions were also
shown to increase PA and mTORC1 signaling and 1-
butanol prevented the activation of mTORC1 signaling
[79]. Combined, the data obtained with 1-butanol
suggested that PLD-derived PA plays a significant role
in the mechanical activation of mTORC1 signaling.
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Although 1-butanol has been used as a PLD inhibitor for
many years, more recent studies have questioned its
specificity by showing that several of the biological effects
of 1-butanol cannot be attributed to its effects on the
synthesis of PA by PLD [80-82]. Thus, we re-examined
whether the mechanically induced increase in PA requires
PLD by using a small-molecule inhibitor of PLD called
5-fluoro-2-indolyl des-chlorohalopemide (FIPI) [80]. To
our surprise, we found that FIPI did not inhibit the passive
stretch-induced increases in PA or mTORC1 signaling,
suggesting that changes in PLD activity were not necessary
for these events [74]. Instead, it was shown that passive
stretch induces an increase in DAG, suggesting that there
could be corresponding increases in DGK activity. Indeed,
a passive stretch was sufficient to increasemembraneDGK
activity, but further experiments showed that the a, b, g,
and q isoforms of DGK were not necessary for the
mechanically induced increase in PA and mTORC1
signaling [74]. These findings prompted us to explore
the potential role of DGKz, and using DGKz knockout
mice, it was found that the passive stretch-induced
increase in PA was almost completely abolished and that
the activation of mTORC1 signaling was markedly
impaired [74]. These data suggested that DGKz is
predominantly responsible for the increase in PA and
contributes to the mechanical activation of mTORC1
signaling (Figure 1). Additional experiments also showed
that the in vivo overexpression of DGKz was sufficient to
induce muscle fiber hypertrophy in a kinase-dependent
manner (i.e. via the synthesis of PA) and that this hyper-
trophic response was largely inhibited by rapamycin [74].
Combined, the results of this study highlight a novel
role for DGKz (but not PLD as previously thought) in the
mechanical activation of PA-mTORC1 signaling and
provide new insights into the potential mechanism(s)
through which mechanical stimuli regulate muscle mass.
Further research is now required to confirm the role of
DGKz in other models of mechanical stimulation (e.g.
eccentric contractions and synergist ablation-induced
mechanical overload) and to determine whether DGKz-
derived PA is sufficient to increase protein synthesis or
decrease protein degradation or both.
Conclusions
Significant progress continues to be made in our under-
standing of the diverse range of molecular mechanisms
that can regulate skeletal muscle mass under various
physiological and pathophysiological conditions. In this
review, we have specifically focused on recent studies
that have significantly advanced our understanding of
the roles that Smad signaling and the synthesis of PA
play in the regulation of muscle mass. It is expected that
these advancements will facilitate the development of
therapies for conditions that are associated with muscle
atrophy/wasting, metabolic disease, and reduced mobi-
lity and ultimately help to improve quality of life.
Abbreviations
ALK, activin receptor-like kinase; BMP, bone morpho-
genic protein; caALK, constitutively active ALK; DAG,
diacylglycerol; DGKz, diacylglycerol kinase zeta isoform;
FIPI, 5-fluoro-2-indolyl des-chlorohalopemide; GDF,
growth differentiation factor; IGF-1, insulin-like growth
factor 1; mTORC, mechanistic target of rapamycin com-
plex; MuRF1, muscle RING-finger protein-1; PA, phospha-
tidic acid; PLD, phospholipase D; PLD1, phospholipase
D1; siRNA, short interfering RNA; TGF-b, transforming
growth factor-beta.
Disclosures
The authors declare that they have no disclosures.
Acknowledgments
This work was supported by the National Institutes of
Health grants AR057347 (TAH) and AR063256 (CAG
and TAH).
References
1. Lee RC, Wang Z, Heo M, Ross R, Janssen I, Heymsfield SB: Total-
body skeletal muscle mass: development and cross-validation
of anthropometric prediction models. Am J Clin Nutr 2000,
72:796-803.
2. Izumiya Y, Hopkins T, Morris C, Sato K, Zeng L, Viereck J, Hamilton JA,
Ouchi N, LeBrasseur NK, Walsh K: Fast/Glycolytic muscle fiber
growth reduces fat mass and improves metabolic parameters
in obese mice. Cell Metab 2008, 7:159-72.
3. Seguin R, Nelson ME: The benefits of strength training for older
adults. Am J Prev Med 2003, 25:141-9.
4. Srikanthan P, Karlamangla AS: Relative muscle mass is inversely
associated with insulin resistance and prediabetes. Findings
from the third National Health and Nutrition Examination
Survey. J Clin Endocrinol Metab 2011, 96:2898-903.
5. Lynch GS: Tackling Australia’s future health problems: devel-
oping strategies to combat sarcopenia–age-related muscle
wasting and weakness. Intern Med J 2004, 34:294-6.
6. Bonaldo P, Sandri M: Cellular and molecular mechanisms of
muscle atrophy. Dis Model Mech 2013, 6:25-39.
7. Sandri M: Signaling in muscle atrophy and hypertrophy.
Physiology (Bethesda) 2008, 23:160-70.
8. Frost RA, Lang CH: Protein kinase B/Akt: a nexus of growth
factor and cytokine signaling in determining muscle mass.
J Appl Physiol 2007, 103:378-87.
9. Bodine SC: mTOR signaling and the molecular adaptation to
resistance exercise. Med Sci Sports Exerc 2006, 38:1950-7.
10. Zacharewicz E, Lamon S, Russell AP:MicroRNAs in skeletalmuscle
and their regulation with exercise, ageing, and disease. Front
Physiol 2013, 4:266.
11. Verhees KJP, Pansters NAM, Schols AMWJ, Langen RCJ: Regulation
of skeletal muscle plasticity by glycogen synthase kinase-3b: a
potential target for the treatment of muscle wasting. Curr
Pharm Des 2013, 19:3276-98.
Page 6 of 9
(page number not for citation purposes)
F1000Prime Reports 2014, 6:20 http://f1000.com/prime/reports/b/6/20
12. Tabebordbar M, Wang ET, Wagers AJ: Skeletal muscle degen-
erative diseases and strategies for therapeutic muscle repair.
Annu Rev Pathol 2013, 8:441-75.
13. Senf SM: Skeletal muscle heat shock protein 70: diverse
functions and therapeutic potential for wasting disorders.
Front Physiol 2013, 4:330.
14. Schakman O, Kalista S, Barbé C, Loumaye A, Thissen JP: Gluco-
corticoid-induced skeletal muscle atrophy. Int J Biochem Cell Biol
2013, 45:2163-72.
15. Sandri M: Protein breakdown in muscle wasting: role of
autophagy-lysosome and ubiquitin-proteasome. Int J Biochem
Cell Biol 2013, 45:2121-9.
16. Ljubicic V, Jasmin BJ: AMP-activated protein kinase at the nexus
of therapeutic skeletal muscle plasticity in Duchenne mus-
cular dystrophy. Trends Mol Med 2013, 19:614-24.
17. Egerman MA, Glass DJ: Signaling pathways controlling skeletal
muscle mass. Crit Rev Biochem Mol Biol 2014, 49:59-68.
18. Wallace MA, Lamon S, Russell AP: The regulation and function of
the striated muscle activator of rho signaling (STARS)
protein. Front Physiol 2012, 3:469.
19. Kumar A, Bhatnagar S, Paul PK: TWEAK and TRAF6 regulate
skeletal muscle atrophy. Curr Opin Clin Nutr Metab Care 2012,
15:233-9.
20. Goodman CA, Mayhew DL, Hornberger TA: Recent progress
toward understanding the molecular mechanisms that reg-
ulate skeletal muscle mass. Cell Signal 2011, 23:1896-906.
21. Lynch GS, Ryall JG: Role of beta-adrenoceptor signaling in
skeletal muscle: implications for muscle wasting and disease.
Physiol Rev 2008, 88:729-67.
22. Goodman CA: The Role of mTORC1 in Regulating Protein
Synthesis and Skeletal Muscle Mass in Response to Various
Mechanical Stimuli. Rev Physiol Biochem Pharmacol 2014.
23. Han HQ, Zhou X, Mitch WE, Goldberg AL: Myostatin/activin
pathway antagonism: molecular basis and therapeutic poten-
tial. Int J Biochem Cell Biol 2013, 45:2333-47.
24. Tsuchida K: The role of myostatin and bone morphogenetic
proteins inmuscular disorders. Expert Opin Biol Ther 2006, 6:147-54.
25. Hornberger TA: Mechanotransduction and the regulation of
mTORC1 signaling in skeletal muscle. Int J Biochem Cell Biol 2011,
43:1267-76.
26. Jacobs BL, Goodman CA, Hornberger TA: The mechanical
activation of mTOR signaling: an emerging role for late
endosome/lysosomal targeting. J Muscle Res Cell Motil 2013.
27. Adams GR, Bamman MM: Characterization and regulation of
mechanical loading-induced compensatory muscle hypertro-
phy. Compr Physiol 2012, 2:2829-70.
28. Miyazono K, Maeda S, Imamura T: BMP receptor signaling:
transcriptional targets, regulation of signals, and signaling
cross-talk. Cytokine Growth Factor Rev 2005, 16:251-63.
29. Moustakas A, Heldin C: The regulation of TGFbeta signal
transduction. Development 2009, 136:3699-714.
30. McPherron AC, Lawler AM, Lee SJ: Regulation of skeletal muscle
mass in mice by a new TGF-beta superfamily member. Nature
1997, 387:83-90.
31. Lee SJ, McPherron AC: Regulation of myostatin activity and
muscle growth. Proc Natl Acad Sci USA 2001, 98:9306-11.
32. Gonzalez-Cadavid NF, Taylor WE, Yarasheski K, Sinha-Hikim I, Ma K,
Ezzat S, Shen R, Lalani R, Asa S, Mamita M, Nair G, Arver S, Bhasin S:
Organization of the human myostatin gene and expression in
healthy men and HIV-infected men with muscle wasting. Proc
Natl Acad Sci USA 1998, 95:14938-43.
33. Zimmers TA, Davies MV, Koniaris LG, Haynes P, Esquela AF,
Tomkinson KN, McPherron AC, Wolfman NM, Lee S: Induction of
cachexia in mice by systemically administered myostatin.
Science 2002, 296:1486-8.
34. Langley B, Thomas M, Bishop A, Sharma M, Gilmour S, Kambadur R:
Myostatin inhibits myoblast differentiation by down-regulating
MyoD expression. J Biol Chem 2002, 277:49831-40.
35. Elkina Y, von Haehling S, Anker SD, Springer J: The role of
myostatin in muscle wasting: an overview. J Cachexia Sarcopenia
Muscle 2011, 2:143-51.
36. Ross S, Hill CS: How the Smads regulate transcription. Int J
Biochem Cell Biol 2008, 40:383-408.
37. Walton KL, Makanji Y, Harrison CA: New insights into the
mechanisms of activin action and inhibition. Mol Cell Endocrinol
2012, 359:2-12.
38. Tsuchida K, Nakatani M, Uezumi A, Murakami T, Cui X: Signal
transduction pathway through activin receptors as a ther-
apeutic target of musculoskeletal diseases and cancer. Endocr J
2008, 55:11-21.
39. Sartori R, Milan G, Patron M, Mammucari C, Blaauw B, Abraham R,
Sandri M: Smad2 and 3 transcription factors control muscle
mass in adulthood. Am J Physiol Cell Physiol 2009, 296:C1248-57.
40. Trendelenburg AU, Meyer A, Rohner D, Boyle J, Hatakeyama S,
Glass DJ: Myostatin reduces Akt/TORC1/p70S6K signaling,
inhibiting myoblast differentiation and myotube size. Am J
Physiol Cell Physiol 2009, 296:C1258-70.
41. Lokireddy S, McFarlane C, Ge X, Zhang H, Sze SK, Sharma M,
Kambadur R: Myostatin induces degradation of sarcomeric
proteins through a Smad3 signalingmechanism during skeletal
muscle wasting. Mol Endocrinol 2011, 25:1936-49.
42. Rodriguez J, Vernus B, Toubiana M, Jublanc E, Tintignac L, Leibovitch S,
Bonnieu A: Myostatin inactivation increases myotube size
through regulation of translational initiation machinery. J Cell
Biochem 2011, 112:3531-42.
43. Lagirand-Cantaloube J, Offner N, Csibi A, Leibovitch MP, Batonnet-
Pichon S, Tintignac LA, Segura CT, Leibovitch SA: The initiation
factor eIF3-f is a major target for atrogin1/MAFbx function in
skeletal muscle atrophy. EMBO J 2008, 27:1266-76.
44. Amirouche A, Durieux A, Banzet S, Koulmann N, Bonnefoy R,
Mouret C, Bigard X, Peinnequin A, Freyssenet D: Down-regulation
of Akt/mammalian target of rapamycin signaling pathway in
response to myostatin overexpression in skeletal muscle.
Endocrinology 2009, 150:286-94.
45. Taylor WE, Bhasin S, Artaza J, Byhower F, Azam M, Willard DH,
Kull FC, Gonzalez-Cadavid N: Myostatin inhibits cell prolifera-
tion and protein synthesis in C2C12 muscle cells. Am J Physiol
Endocrinol Metab 2001, 280:E221-8.
46. Welle S, Bhatt K, Pinkert CA: Myofibrillar protein synthesis in
myostatin-deficient mice. Am J Physiol Endocrinol Metab 2006, 290:
E409-15.
47. Welle S, Burgess K, Mehta S: Stimulation of skeletal muscle
myofibrillar protein synthesis, p70 S6 kinase phosphorylation,
and ribosomal protein S6 phosphorylation by inhibition of
myostatin in mature mice. Am J Physiol Endocrinol Metab 2009,
296:E567-72.
48. Welle S, Mehta S, Burgess K: Effect of postdevelopmental
myostatin depletion on myofibrillar protein metabolism. Am
J Physiol Endocrinol Metab 2011, 300:E993-E1001.
Page 7 of 9
(page number not for citation purposes)
F1000Prime Reports 2014, 6:20 http://f1000.com/prime/reports/b/6/20
49. Hulmi JJ, Oliveira BM, Silvennoinen M, Hoogaars WMH, Ma H,
Pierre P, Pasternack A, Kainulainen H, Ritvos O: Muscle protein
synthesis, mTORC1/MAPK/Hippo signaling, and capillary
density are altered by blocking of myostatin and activins.
Am J Physiol Endocrinol Metab 2013, 304:E41-50.
50. Schiaffino S, Dyar KA, Ciciliot S, Blaauw B, Sandri M: Mechanisms
regulating skeletal muscle growth and atrophy. FEBS J 2013,
280:4294-314.
51. Lokireddy S, Mouly V, Butler-Browne G, Gluckman PD, Sharma M,
Kambadur R, McFarlane C: Myostatin promotes the wasting of
human myoblast cultures through promoting ubiquitin-
proteasome pathway-mediated loss of sarcomeric proteins.
Am J Physiol Cell Physiol 2011, 301:C1316-24.
52. Lokireddy S, Wijesoma IW, Sze SK, McFarlane C, Kambadur R,
Sharma M: Identification of atrogin-1-targeted proteins during
the myostatin-induced skeletal muscle wasting. Am J Physiol Cell
Physiol 2012, 303:C512-29.
53. Goodman CA, McNally RM, Hoffmann FM, Hornberger TA: Smad3
induces atrogin-1, inhibits mTOR and protein synthesis, and
promotes muscle atrophy in vivo. Mol Endocrinol 2013,
27:1946-57.
54. Hitachi K, Nakatani M, Tsuchida K: Myostatin signaling regulates
Akt activity via the regulation of miR-486 expression. Int J
Biochem Cell Biol 2014, 47:93-103.
55. Mueller TD, Nickel J: Promiscuity and specificity in BMP
receptor activation. FEBS Lett 2012, 586:1846-59.
56. Sartori R, Schirwis E, Blaauw B, Bortolanza S, Zhao J, Enzo E,
Stantzou A, Mouisel E, Toniolo L, Ferry A, Stricker S, Goldberg AL,
Dupont S, Piccolo S, Amthor H, Sandri M: BMP signaling controls
muscle mass. Nat Genet 2013, 45:1309-18.
57. Winbanks CE, Chen JL, Qian H, Liu Y, Bernardo BC, Beyer C,
Watt KI, Thomson RE, Connor T, Turner BJ, McMullen JR, Larsson L,
McGee SL, Harrison CA, Gregorevic P: The bone morphogenetic
protein axis is a positive regulator of skeletal muscle mass. J
Cell Biol 2013, 203:345-57.
58. Moresi V, Williams AH, Meadows E, Flynn JM, Potthoff MJ, McAnally J,
Shelton JM, Backs J, KleinWH, Richardson JA, Bassel-Duby R, Olson EN:
Myogenin and class II HDACs control neurogenic muscle
atrophy by inducing E3 ubiquitin ligases. Cell 2010, 143:35-45.
59. Wang X, Devaiah SP, Zhang W, Welti R: Signaling functions of
phosphatidic acid. Prog Lipid Res 2006, 45:250-78.
60. Fang Y, Vilella-Bach M, Bachmann R, Flanigan A, Chen J: Phospha-
tidic acid-mediated mitogenic activation of mTOR signaling.
Science 2001, 294:1942-5.
61. Park I, Bachmann R, Shirazi H, Chen J: Regulation of ribosomal S6
kinase 2 by mammalian target of rapamycin. J Biol Chem 2002,
277:31423-9.
62. Avila-Flores A, Santos T, Rincón E, Mérida I: Modulation of the
mammalian target of rapamycin pathway by diacylglycerol
kinase-produced phosphatidic acid. J Biol Chem 2005,
280:10091-9.
63. Tang W, Yuan J, Chen X, Gu X, Luo K, Li J, Wan B, Wang Y, Yu L:
Identification of a novel human lysophosphatidic acid acyl-
transferase, LPAAT-theta, which activates mTOR pathway. J
Biochem Mol Biol 2006, 39:626-35.
64. O’Neil TK, Duffy LR, Frey JW, Hornberger TA: The role of
phosphoinositide 3-kinase and phosphatidic acid in the
regulation of mammalian target of rapamycin following
eccentric contractions. J Physiol (Lond) 2009, 587:3691-701.
65. You JS, Frey JW, Hornberger TA:Mechanical stimulation induces
mTOR signaling via an ERK-independent mechanism: impli-
cations for a direct activation of mTOR by phosphatidic acid.
PLoS ONE 2012, 7:e47258.
66. Foster DA: Regulation of mTOR by phosphatidic acid? Cancer
Res 2007, 67:1-4.
67. Ballou LM, Jiang Y, Du G, Frohman MA, Lin RZ: Ca(2+)- and
phospholipase D-dependent and -independent pathways
activate mTOR signaling. FEBS Lett 2003, 550:51-6.
68. Hornberger TA, Chu WK, Mak YW, Hsiung JW, Huang SA, Chien S:
The role of phospholipase D and phosphatidic acid in the
mechanical activation of mTOR signaling in skeletal muscle.
Proc Natl Acad Sci USA 2006, 103:4741-6.
69. Takahara T, Hara K, Yonezawa K, Sorimachi H, Maeda T: Nutrient-
dependent multimerization of the mammalian target of
rapamycin through the N-terminal HEAT repeat region. J Biol
Chem 2006, 281:28605-14.
70. Ha SH, Kim D, Kim I, Kim JH, Lee MN, Lee HJ, Kim JH, Jang SK, Suh P,
Ryu SH: PLD2 forms a functional complex with mTOR/raptor
to transduce mitogenic signals. Cell Signal 2006, 18:2283-91.
71. Yoon M, Sun Y, Arauz E, Jiang Y, Chen J: Phosphatidic acid
activates mammalian target of rapamycin complex 1
(mTORC1) kinase by displacing FK506 binding protein 38
(FKBP38) and exerting an allosteric effect. J Biol Chem 2011,
286:29568-74.
72. Veverka V, Crabbe T, Bird I, Lennie G, Muskett FW, Taylor RJ,
Carr MD: Structural characterization of the interaction of
mTOR with phosphatidic acid and a novel class of inhibitor:
compelling evidence for a central role of the FRB domain in
small molecule-mediated regulation of mTOR. Oncogene 2008,
27:585-95.
73. Jaafar R, de Larichaudy J, Chanon S, Euthine V, Durand C, Naro F,
Bertolino P, Vidal H, Lefai E, Némoz G: Phospholipase D regulates
the size of skeletal muscle cells through the activation of
mTOR signaling. Cell Commun Signal 2013, 11:55.
74. You J, Lincoln HC, Kim C, Frey JW, Goodman CA, Zhong X,
Hornberger TA: The Role of Diacylglycerol Kinase z and
Phosphatidic Acid in the Mechanical Activation of Mamma-
lian Target of Rapamycin (mTOR) Signaling and Skeletal
Muscle Hypertrophy. J Biol Chem 2014, 289:1551-63.
75. Goodman CA, Mabrey DM, Frey JW, Miu MH, Schmidt EK, Pierre P,
Hornberger TA: Novel insights into the regulation of skeletal
muscle protein synthesis as revealed by a new nonradioactive
in vivo technique. FASEB J 2011, 25:1028-39.
76. Sandri M, Sandri C, Gilbert A, Skurk C, Calabria E, Picard A, Walsh K,
Schiaffino S, Lecker SH, Goldberg AL: Foxo transcription factors
induce the atrophy-related ubiquitin ligase atrogin-1 and
cause skeletal muscle atrophy. Cell 2004, 117:399-412.
77. Stitt TN, Drujan D, Clarke BA, Panaro F, Timofeyva Y, Kline WO,
Gonzalez M, Yancopoulos GD, Glass DJ: The IGF-1/PI3K/Akt
Page 8 of 9
(page number not for citation purposes)
F1000Prime Reports 2014, 6:20 http://f1000.com/prime/reports/b/6/20
pathway prevents expression of muscle atrophy-induced
ubiquitin ligases by inhibiting FOXO transcription factors.
Mol Cell 2004, 14:395-403.
78. Jaafar R, Zeiller C, Pirola L, Di Grazia A, Naro F, Vidal H, Lefai E,
Némoz G: Phospholipase D regulates myogenic differentiation
through the activation of both mTORC1 and mTORC2
complexes. J Biol Chem 2011, 286:22609-21.
79. O’Neil TK, Duffy LR, Frey JW, Hornberger TA: The role of
phosphoinositide 3-kinase and phosphatidic acid in the
regulation of mammalian target of rapamycin following
eccentric contractions. J Physiol (Lond) 2009, 587:3691-701.
80. Su W, Yeku O, Olepu S, Genna A, Park J, Ren H, Du G, Gelb MH,
Morris AJ, Frohman MA: 5-Fluoro-2-indolyl des-chlorohalopemide
(FIPI), a phospholipase D pharmacological inhibitor that alters
cell spreading and inhibits chemotaxis. Mol Pharmacol 2009,
75:437-46.
81. Yanase Y, Carvou N, Frohman MA, Cockcroft S: Reversible bleb
formation in mast cells stimulated with antigen is Ca2+/
calmodulin-dependent and bleb size is regulated by ARF6.
Biochem J 2010, 425:179-93.
82. Sato T, Hongu T, Sakamoto M, Funakoshi Y, Kanaho Y: Molecular
mechanisms of N-formyl-methionyl-leucyl-phenylalanine-
induced superoxide generation and degranulation in mouse
neutrophils: phospholipase D is dispensable. Mol Cell Biol 2013,
33:136-45.
Page 9 of 9
(page number not for citation purposes)
F1000Prime Reports 2014, 6:20 http://f1000.com/prime/reports/b/6/20
